Levera XR 750 Tablet contains Levetiracetam 750 mg, an antiepileptic medication indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure propagation. The extended-release formulation of Levera XR allows for once-daily dosing, enhancing patient compliance and maintaining steady plasma drug concentrations. This medication is typically prescribed as adjunctive therapy in adults and pediatric patients aged 12 years and above. Levera XR 750 mg should be administered orally with or without food, and dosage adjustments may be necessary based on renal function and clinical response. Common adverse effects include somnolence, dizziness, headache, and fatigue, while serious but rare side effects may involve behavioral changes, mood alterations, or hypersensitivity reactions. Regular monitoring and consultation with a healthcare provider are essential to optimize therapeutic outcomes and minimize risks. Levera XR 750 Tablet should be used under strict medical supervision, with careful consideration of patient history and concomitant medications to avoid potential drug interactions.